<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00132509</url>
  </required_header>
  <id_info>
    <org_study_id>2000.208</org_study_id>
    <nct_id>NCT00132509</nct_id>
  </id_info>
  <brief_title>FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke</brief_title>
  <official_title>Comparison of the Classical Rt-PA Procedure (0.9mg/kg Over 60 Minutes) With a Longer Procedure With Lower Dose (0.8mg/kg Over 90 Minutes) in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <brief_summary>
    <textblock>
      Data from the literature have suggested that a longer time of thrombolysis might be more
      effective in ischemic stroke. We, the investigators at Hospices Civils de Lyon, have designed
      a randomized protocol to test this hypothesis. Moreover, the therapeutic window is 7 hours.

      Rt-PA (alteplase) is injected intravenously in the 2 arms of the study for a duration of 60
      minutes in the arm with a &quot;classical dose&quot; and 90 minutes in the arm with a &quot;low dose-longer
      infusion&quot;.

      This is a study of the outcome at 90 days.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    End of promotion by the sponsor
  </why_stopped>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin score</measure>
    <time_frame>day 90</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>DFIL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NINDS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFIL</intervention_name>
    <description>Alteplase : 0.8mg/kg over 90 minutes</description>
    <arm_group_label>DFIL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NINDS</intervention_name>
    <description>Alteplase : 0.9mg/kg over 60 minutes</description>
    <arm_group_label>NINDS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms of ischemic stroke

          -  Presence of a deficit measurable with National Institutes of Health Stroke Scale
             (NIHSS)

          -  Lack of any hemorrhagic lesion on the computed tomography (CT) scan at entry

          -  Time of therapy less than 7 hours after onset of stroke

          -  Permanent or aggravating symptoms

          -  Ages 18-81

        Exclusion Criteria:

          -  Lack of cerebral infarction or of cranial trauma within 3 weeks before therapy

          -  No surgery within 14 days before therapy

          -  History of cerebral bleeding

          -  Blood pressure: systolic &gt;185 mmHg and/or diastolic &gt;110 mmHg

          -  Minor symptoms or symptoms rapidly improving

          -  Gastro-intestinal or urinary hemorrhage within 21 days

          -  Arterial puncture within 7 days before therapy

          -  Epileptic seizure at the beginning of stroke

          -  Patients under oral anticoagulants or having received heparin within 48 hours, and
             with elevated activated partial thromboplastin time (aPTT)

          -  Patients with elevated International Normalized Ratio (INR) or thrombocyte count &lt; 100
             x 10^9

          -  Blood glucose value &lt; 2.7 mmol/l or &gt; 22.2 mmol/l

          -  Cardiac, pulmonary, hepatic or renal failure, not allowing a study over 3 months

          -  History of gastric ulcer within 15 days; gestation and menstruation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul TROUILLAS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2005</study_first_submitted>
  <study_first_submitted_qc>August 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2005</study_first_posted>
  <last_update_submitted>July 21, 2011</last_update_submitted>
  <last_update_submitted_qc>July 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Pr Paul TROUILLAS</name_title>
    <organization>Service de Neurologie, Hôpital Neurologique, Hospices Civils de Lyon</organization>
  </responsible_party>
  <keyword>rt-PA</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>Acute ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

